Evidence map›Paper›PMID 34163888›Full record

ArticleChemical science2021

Click activated protodrugs against cancer increase the therapeutic potential of chemotherapy through local capture and activation.

Kui Wu, Nathan A Yee, Sangeetha Srinivasan, Amir Mahmoodi, Michael Zakharian, Jose M Mejia Oneto, Maksim Royzen

Erratum issuedOpen access · diamondAbstract read
In one paragraph

Article in Chemical science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
9.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 114 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Biocompatible Chemistry: A Plug-and-Play Toolbox for Chemical Biology Research.Chembiochem : a European journal of chemical biology · 2025
    Review
  10. Article
  11. Development of a First-in-Class Click Chemistry-Based Cancer Therapeutic, from Preclinical Evaluation to a First-in-Human Dose Escalation Clinical Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025
    Article
  12. Article
  13. Click-Triggered Bioorthogonal Bond-Cleavage Reactions.Topics in current chemistry (Cham) · 2025
    Review
  14. Toward Realization of Bioorthogonal Chemistry in the Clinic.Topics in current chemistry (Cham) · 2025
    Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Kui WuUniversity at Albany, SUNY 1400 Washington Ave., LS-1136 Albany NY 12222 USA mroyzen@albany.edu.
Nathan A YeeShasqi, Inc. 665 3rd St., Suite 501 San Francisco CA 94107 USA jose@shasqi.com.
Sangeetha SrinivasanShasqi, Inc. 665 3rd St., Suite 501 San Francisco CA 94107 USA jose@shasqi.com.
Amir MahmoodiShasqi, Inc. 665 3rd St., Suite 501 San Francisco CA 94107 USA jose@shasqi.com.
Michael ZakharianShasqi, Inc. 665 3rd St., Suite 501 San Francisco CA 94107 USA jose@shasqi.com.
Jose M Mejia OnetoShasqi, Inc. 665 3rd St., Suite 501 San Francisco CA 94107 USA jose@shasqi.com.
Maksim RoyzenUniversity at Albany, SUNY 1400 Washington Ave., LS-1136 Albany NY 12222 USA mroyzen@albany.edu.ORCID https://orcid.org/0000-0002-2930-2171
Shaqra University · SAPurchase College · US

Funding

Material-guided delivery and local activation of bioorthogonal prodrugsR44GM130240 · NIGMS · TAMBO, INC. · PI SRINIVASAN, SANGEETHA · 2019 to 2021
$1.7M
Development of Catch and Release Approach for Multi-Drug Local Delivery of ChemotherapiesR21CA228997 · NCI · STATE UNIVERSITY OF NEW YORK AT ALBANY · PI ROYZEN, MAKSIM · 2018 to 2020
$606k
Material guided drug delivery for pediatric tumors using an implantable biomaterial and bio-orthogonal chemistryR43HD093495 · NICHD · TAMBO, INC. · PI SRINIVASAN, SANGEETHA · 2018 to 2018
$300k
NCI NIH HHS R21 CA228997NICHD NIH HHS R43 HD093495NIGMS NIH HHS R44 GM130240
6 · The paper itself

Abstract

A desired goal of targeted cancer treatments is to achieve high tumor specificity with minimal side effects. Despite recent advances, this remains difficult to achieve in practice as most approaches rely on biomarkers or physiological differences between malignant and healthy tissue, and thus benefit only a subset of patients in need of treatment. To address this unmet need, we introduced a Click Activated Protodrugs Against Cancer (CAPAC) platform that enables targeted activation of drugs at a specific site in the body,

Identifiers

PMID34163888
PMCPMC8179178
OpenAlexW3121097086

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.